ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.1 NOK | +1.71% |
|
+10.14% | -91.78% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-04-17
- Business Update Call
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.93
NOK
Average target price
6.5
NOK
Spread / Average Target
-34.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -91.78% | 31.22M | |
| +48.77% | 42.16B | |
| -0.09% | 42.07B | |
| +5.69% | 39.77B | |
| -11.36% | 26.68B | |
| +4.48% | 24.68B | |
| -22.84% | 18.68B | |
| -1.32% | 12.11B | |
| +26.38% | 11.99B | |
| +6.24% | 11.06B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs' Cancer Vaccine Prolongs Patient Survival In Early-stage Study
